Dr. Vokes on Pembrolizumab Plus Chemotherapy and Radiation in Lung Cancer

Everett Vokes, MD
Published: Monday, Aug 14, 2017



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.

According to Vokes, pembrolizumab, chemotherapy, and radiation is a relevant treatment option for patients with lung cancer. There was a trial investigating this for patients with nonsquamous non-small cell lung cancer (NSCLC), which accrued 500 patients. It showed no difference in progression-free survival and overall survival, states Vokes.
 


Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.

According to Vokes, pembrolizumab, chemotherapy, and radiation is a relevant treatment option for patients with lung cancer. There was a trial investigating this for patients with nonsquamous non-small cell lung cancer (NSCLC), which accrued 500 patients. It showed no difference in progression-free survival and overall survival, states Vokes.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x